Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CG Oncology (CGON) Free Cash Flow: 2023-2025

Historic Free Cash Flow for CG Oncology (CGON) over the last 3 years, with Sep 2025 value amounting to -$39.0 million.

  • CG Oncology's Free Cash Flow fell 144.95% to -$39.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$117.1 million, marking a year-over-year decrease of 61.06%. This contributed to the annual value of -$78.9 million for FY2024, which is 72.83% down from last year.
  • Per CG Oncology's latest filing, its Free Cash Flow stood at -$39.0 million for Q3 2025, which was down 39.50% from -$27.9 million recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's Free Cash Flow peaked at -$8.0 million during Q1 2023, and registered a low of -$39.0 million during Q3 2025.
  • For the 3-year period, CG Oncology's Free Cash Flow averaged around -$20.1 million, with its median value being -$16.1 million (2024).
  • Data for CG Oncology's Free Cash Flow shows a maximum YoY tumbled of 225.87% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows CG Oncology's Free Cash Flow stood at -$14.6 million in 2023, then tumbled by 42.51% to -$20.9 million in 2024, then plummeted by 144.95% to -$39.0 million in 2025.
  • Its last three reported values are -$39.0 million in Q3 2025, -$27.9 million for Q2 2025, and -$29.3 million during Q1 2025.